Patents Assigned to AbbVie Biotechnology Ltd.
  • Patent number: 10022503
    Abstract: Exemplary embodiments provide a needle shield remover that reliably engages with a distal cap of an automatic injection device and with one or more needle shields coupled to a syringe of the device. When a user removes the distal cap, the needle shield remover reliably removes the needle shields (e.g., a soft needle shield and a rigid needle shield) from the syringe, thereby exposing the injection needle for performing an injection. In an exemplary assembly method, a needle shield remover is engaged to a needle shield coupled to a syringe, prior to insertion of the syringe and needle shield remover assembly into a housing of the device. This exemplary assembly method allows visual inspection, outside the housing of the device, to ensure that the needle shield remover is correctly and reliably engaged to the needle shield before the syringe and needle shield remover assembly is inserted into the housing.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: July 17, 2018
    Assignees: AbbVie Biotechnology Ltd, Elcam Medical Agricultural Cooperative Association Ltd
    Inventors: Joseph F. Julian, Chuan Li, Philip D. Anderson, Linas P. Laurusonis, Lior Raday, Ehud Carmel, Lior Marli, David Daily, Guy Keenan
  • Patent number: 9950066
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: April 24, 2018
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: 9913902
    Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: March 13, 2018
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Min M. Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
  • Patent number: 9878102
    Abstract: Exemplary embodiments provide automatic injection devices, housing components for automatic injection devices and methods for fabricating the same. An exemplary housing of an automatic injection device may be overmolded with one or more gripping surfaces to facilitate gripping and manipulation of the automatic injection device by a user when performing an injection. In an exemplary embodiment, an overmolded left gripping surface may extend along a left side of the housing and an overmolded right gripping surface may extend along a right side of the housing opposite to the left side.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: January 30, 2018
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Joseph F. Julian, Chuan Li, Aaron B. Eiger, Mark Kurth, Sabrina Katz, Adam Callif, James C. Stango
  • Patent number: 9821117
    Abstract: Exemplary embodiments provide wearable automatic injection devices for subcutaneously injecting a therapeutic agent into a patient's body at controlled rates, for example, in a single bolus. Exemplary embodiments provide methods for assembling wearable automatic injection devices for subcutaneously injecting a therapeutic agent into a patient's body at controlled rates. Exemplary embodiments provide methods for using wearable automatic injection devices for subcutaneously injecting a therapeutic agent into a patient's body at controlled rates.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: November 21, 2017
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Philip D. Anderson, Joseph F. Julian, Linas P. Laurusonis, Timothy Parmer, Travis Yoch, Samuel M. Jang, Sean Corrigan, Tomas Matusaitis, William Fienup, Chris Strahm
  • Patent number: 9764090
    Abstract: An injection device comprises a syringe extendible against a spring bias from a retracted position in a housing to a projecting injecting position. A spring biased plunger has collapsible elbows which, when the plunger is released, initially engage the end of the syringe to drive it to the projecting position, whereupon arresting of the syringe movement causes the elbows to collapse inside the syringe to allow the plunger to engage and drive the bung.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: September 19, 2017
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Stephen Bicknell, Joseph F. Julian, William L. Rudzena
  • Patent number: 9750808
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 5, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: 9738714
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 22, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: 9732152
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 15, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: 9669093
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: June 6, 2017
    Assignee: AbbVie Biotechnology Ltd
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Patent number: 9624295
    Abstract: The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of psoriatic arthritis in a subject.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: April 18, 2017
    Assignee: Abbvie Biotechnology Ltd.
    Inventors: John R. Medich, Robert L. Wong, Renee J. Perdok, Eric H. Sasso, Rebecca S. Hoffman, Phillip Mease, Christopher T. Ritchlin
  • Patent number: 9605064
    Abstract: The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNF? activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNF? activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNF? antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNF? activity, such as psoriasis.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: March 28, 2017
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Martin M. Okun, Rebecca S. Hoffman, Jonathan Barker
  • Patent number: 9572938
    Abstract: An automatic injection device for providing a subcutaneous injection is disclosed. The device includes a syringe movably disposed in a housing and including a barrel portion, a needle and a bung for sealing the barrel portion. The device includes a plunger for moving the syringe towards a first open end of the housing such that the needle projects from the first end, and for subsequently applying pressure to the bung. The plunger includes a rod connected at a first end to the bung, a compressible expanded central portion, and a flange between a second end of the rod and the central portion. The device also includes a biasing mechanism for biasing the plunger towards the first open end of the housing, the biasing mechanism disposed about the second end of the rod between the flange and a second end of the housing.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: February 21, 2017
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Joseph F. Julian, Steven Rolfe, Stephen Bicknell, Jeremy Marshall
  • Patent number: 9561328
    Abstract: Exemplary embodiments provide a syringe plunger formed of a polymeric material. The syringe plunger includes a pressurizer disposed at a proximal end, and a distal end bifurcated into a first plunger arm having a first conical surface and a second conical surface, and a second plunger arm having a first conical surface and a second conical surface. The distal end includes a first contact surface defined by the first conical surface of the first plunger arm and the first conical surface of the second plunger arm, the first contact surface configured to initially contact a firing engagement mechanism, the first contact surface disposed at a first angle of between about 40° and about 80° relative to a longitudinal axis of the syringe plunger.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: February 7, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Sherwin S. Shang, Esra Ozdaryal, Marc M. Plew, William P. Szechinski
  • Patent number: 9546212
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: January 17, 2017
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
  • Patent number: 9512216
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: December 6, 2016
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Elliot K. Chartash, Philip Yan, George R. Granneman
  • Patent number: 9499615
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: November 22, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Patent number: 9486584
    Abstract: A method for treating a disorder using an automatic injection device is disclosed. The device includes a syringe movably disposed in a housing and including a barrel portion, a needle and a bung for sealing the barrel portion. The device includes a syringe actuation component for moving the syringe towards a first open end of the housing such that the needle projects from the first end, and for subsequently applying pressure to the bung. The syringe actuation component includes a pressurizer, a rod comprising a compressible portion projecting therefrom, and a flange between a second end of the rod and the compressible portion. The device also includes a biasing mechanism for biasing the syringe actuation component towards the first open end of the housing, the biasing mechanism disposed about the second end of the rod between the flange and a second end of the housing.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: November 8, 2016
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Joseph F. Julian, Steven Rolfe, Stephen Bicknell, Jeremy Marshall
  • Patent number: 9399061
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: July 26, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hartmut Kupper, Jeffrey D. Kent, Mary A. Cifaldi, John L. Perez, Gerd R. Burmester, Philip Mease, Daniel J. Lovell, Edward Keystone, Arthur Kavanaugh
  • Patent number: D772733
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: November 29, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Peter C. Stueckemann, Max Bock-Aronson, Christopher Alan Harris